Immunoprophylactic control of bovine babesiosis: role of exoantigens of Babesia.
A major breakthrough in babesiosis vaccine research was achieved with the development of methods for continuous propagation in vitro of Babesia parasites. The development of a soluble, exoantigen-containing immunogen, free of erythrocytic antigens, has been proposed as a practical and realistic means of immunoprophylactic control of babesiosis. Such immunogens have been tested for immunogenicity of different strains, minimal protective dose, and protective efficacy of a combined B. bovis-B. bigemina immunogen. During the last 7 years, most of these aspects have been studied in a co-operative research programme between the University of Illinois and the Veterinary Research Institute of Venezuela. The Babesia exoantigen vaccine prevents clinical disease, is effective against different parasite strains, induces protective immunity for at least 13 months, does not immunize against host blood groups, is antigenically stable for at least 3 years at 4 degrees C, and is available in large quantities. Continued improvement of currently available culture-derived immunogens will best guarantee the successful production of food-producing animals in the tropics. Since July 1984, 16 field vaccination trials have been conducted in 7 states of Venezuela in areas where large-scale dairy and beef production is crucial for the livestock industry. These ranches encompassed a cattle production of 14,000, of which 3000 have been vaccinated with a combined B. bovis-B. bigemina immunogen in 2 subcutaneous inoculations with a 4-week interval. In the first 5 trials, a 1-year monitoring period following vaccination and natural tick exposure indicated that the culture-derived vaccine has effectively controlled the clinical manifestation of infection. Studies on antigen characterization are shifting the emphasis from crude antigenic preparations to purified polypeptides, isolated and identified using new biochemical techniques. Current research efforts are directed toward isolation of protective antigens and the production of synthetic vaccines. Until optimal molecular vaccines are developed, a polyvalent inactivated B. bovis-B. bigemina immunogen may offer the best combination of potency, efficacy and safety available for effective immunoprophylaxis against bovine babesiosis.
Montenegro-James
S
S
Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana 61801.
D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology*; D001403:Babesia / Q000276:immunology*; D001404:Babesiosis / Q000517:prevention & control*; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control*; D014611:Vaccination / Q000662:veterinary; D014612:Vaccines
D000953:Antigens, Protozoan; D014612:Vaccines